arsenic trioxide has been researched along with Multiple Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ammatuna, E; Ardiri, D; Centonze, D; Divona, M; Lo-Coco, F; Montefusco, E; Pacilli, M | 1 |
| Low-Beer, TS; Robertson, DA | 1 |
2 other study(ies) available for arsenic trioxide and Multiple Sclerosis
| Article | Year |
|---|---|
Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Male; Mitoxantrone; Multiple Sclerosis; Oxides; Remission Induction; Topoisomerase II Inhibitors; Treatment Outcome | 2009 |
Long term consequences of arsenical treatment for multiple sclerosis.
Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Carcinoma, Transitional Cell; Humans; Hypertension, Portal; Male; Multiple Sclerosis; Oxides; Urinary Bladder Neoplasms | 1983 |